ICU Medical (NASDAQ:ICUI) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a research note published on Tuesday, January 23rd. Zacks Investment Research currently has $266.00 price target on the medical instruments supplier’s stock.

According to Zacks, “ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. They are one of the world’s leading pure-play infusion therapy companies, with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps, dedicated and non-dedicated IV sets and needlefree connectors, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. In addition, they manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for hazardous IV drugs, and cardiac monitoring systems to optimize patient fluid levels. “

Separately, KeyCorp began coverage on ICU Medical in a research note on Tuesday, October 17th. They issued a sector weight rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. ICU Medical presently has an average rating of Hold and a consensus price target of $266.00.

Shares of ICU Medical (NASDAQ:ICUI) traded up $5.90 during midday trading on Tuesday, hitting $226.50. The company’s stock had a trading volume of 41,105 shares, compared to its average volume of 95,620. The company has a market capitalization of $4,408.59, a PE ratio of 147.08, a PEG ratio of 2.31 and a beta of 0.42. ICU Medical has a 12 month low of $142.01 and a 12 month high of $240.20. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 4.65.

In related news, Director Joseph R. Saucedo sold 2,000 shares of ICU Medical stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $216.06, for a total value of $432,120.00. Following the completion of the sale, the director now directly owns 554,364 shares in the company, valued at $119,775,885.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Scott E. Lamb sold 23,624 shares of ICU Medical stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $220.00, for a total value of $5,197,280.00. Following the completion of the sale, the chief financial officer now owns 29,723 shares of the company’s stock, valued at $6,539,060. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,348 shares of company stock valued at $6,014,640. 13.60% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its position in shares of ICU Medical by 3.4% during the 4th quarter. BlackRock Inc. now owns 1,879,874 shares of the medical instruments supplier’s stock worth $406,052,000 after buying an additional 62,605 shares during the period. Janus Henderson Group PLC grew its position in shares of ICU Medical by 17.6% during the 3rd quarter. Janus Henderson Group PLC now owns 1,684,094 shares of the medical instruments supplier’s stock worth $312,989,000 after buying an additional 251,793 shares during the period. Vanguard Group Inc. lifted its holdings in shares of ICU Medical by 16.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,304,282 shares of the medical instruments supplier’s stock valued at $224,989,000 after purchasing an additional 183,133 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of ICU Medical by 0.9% during the 3rd quarter. Wells Fargo & Company MN now owns 560,756 shares of the medical instruments supplier’s stock valued at $104,217,000 after purchasing an additional 5,044 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of ICU Medical by 3.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 432,281 shares of the medical instruments supplier’s stock valued at $80,122,000 after purchasing an additional 14,537 shares in the last quarter. Institutional investors own 77.82% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/icu-medical-icui-upgraded-at-zacks-investment-research.html.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply